Drug firm IOL Chemicals and Pharmaceuticals (IOLCP) today said it has received the certificate of suitability (CEP) from European health regulator for its manufacturing facilities for the non-steroidal anti-inflammatory drug 'Ibuprofen'.
The CEP has been given by the European Directorate for the Quality of Medicines and Healthcare (EDQM), the company said in a filing to the Bombay Stock Exchange (BSE).
EQDM is the technical secretariat of the European Pharmacopoeia Commission.
CEPs are recognised by the signatory member states of the European Pharmacopoeia Commission. All medicines sold in the member states of the European Pharmacopoeia must comply with these quality standards.
Shares of IOLCP were trading at Rs 61.85 on the BSE in the afternoon trade, up 11.74 per cent from its previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app